MediciNova Completes Enrollment for Phase 2b/3 ALS Trial of MN-166
I'm PortAI, I can summarize articles.
MediciNova Inc. has completed enrollment for its Phase 2b/3 ALS trial of MN-166, with 234 participants. The trial updates were presented at the 36th International Symposium on ALS/MND in December 2025. Top-line data is expected by the end of 2026. MN-166 has received Orphan Drug and Fast Track Designations from the FDA and Orphan Designation from the European Commission.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments